BioCardia prices $6 million public offering of common stock and warrants
PositiveFinancial Markets

BioCardia has successfully priced a $6 million public offering of common stock and warrants, marking a significant step in its financial strategy. This move not only strengthens the company's capital base but also signals confidence in its growth potential. Investors are likely to view this offering as a positive development, as it provides BioCardia with the necessary funds to advance its innovative therapies and expand its market presence.
— Curated by the World Pulse Now AI Editorial System